Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease

Blood

Volumn 118, Issue 16, 2011, Pages 4472-4479

  Jacobsohn, David A ^a   Arora, Mukta ^b   Klein, John P ^c   Hassebroek, Anna ^d   Flowers, Mary E ^e   Cutler, Corey S ^f   Urbano Ispizua, Alvaro ^g   Bolwell, Brian J ^h   Antin, Joseph H ^f   Boyiadzis, Michael ⁱ   Cahn, Jean Yves ^j   Cairo, Mitchell S ^k   Herzig, Roger H ^l   Isola, Luis M ^m   Klumpp, Thomas R ⁿ   Lee, Stephanie J ^e   Petersdorf, Effie W ^e   Santarone, Stella ^o   Gale, Robert P ^p   Schouten, Harry C ^q   Spellman, Stephen R ^d   Weisdorf, Daniel J ^b   Wingard, John R ^r   Horowitz, Mary M ^c   Pavletic, Steven Z ^s   more..

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g HOSPITAL CLÍNIC   (Spain)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j HÔPITAL MICHALLON   (France)

^k NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^l UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^m MOUNT SINAI MEDICAL CENTER   (United States)

ⁿ TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

^o Ospedale Civile BMT Center Pescara   (Italy)

^p CELGENE CORPORATION   (United States)

^q MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^r UNIVERSITY OF FLORIDA   (United States)

^s NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; AGE; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE ASSOCIATION; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NONRELAPSE MORTALITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTE COUNT;

EID: 80054832128     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-349068     Document Type: Article

References (36)

1. Lee SJ, Vogelsang G, Flowers ME. Chronic graftversus- host disease. Biol Blood Marrow Transplant. 2003;9(4):215-233.
2. Zecca M, Prete A, Rondelli R, et al. Chronic graftversus- host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002; 100(4):1192-1200. (Pubitemid 34864271)
3. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328(9):593-602. (Pubitemid 23065358)
4. Pavletic SZ, Smith LM, Bishop MR, et al. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol. 2005;78(4):265-274. (Pubitemid 40471118)
5. Akpek G, Zahurak ML, Piantadosi S, et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood. 2001;97(5): 1219-1226. (Pubitemid 32183742)
6. Akpek G, Lee SJ, Flowers ME, et al. Performance of a new clinical grading system for chronic graftversus- host disease: a multicenter study. Blood. 2003;102(3):802-809. (Pubitemid 36917767)
7. Arora M, Burns LJ, Davies SM, et al. Chronic graft-versus-host disease: a prospective cohort study. Biol Blood Marrow Transplant. 2003;9(1): 38-45. (Pubitemid 41123052)
8. Arora M, Nagaraj S, Wagner JE, et al. Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB). Biol Blood Marrow Transplant. 2007; 13(10):1145-1152. (Pubitemid 47413011)
9. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002;100(2):406-414. (Pubitemid 34761100)
10. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood. 1989;74(4):1428-1435. (Pubitemid 19227458)
11. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72(2):546-554.
12. Klein AK, Patel DD, Gooding ME, et al. T-cell recovery in adults and children following umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2001;7(8):454-466. (Pubitemid 32952319)
13. Godthelp BC, van Tol MJ, Vossen JM, van Den Elsen PJ. T-cell immune reconstitution in pediatric leukemia patients after allogeneic bone marrow transplantation with T-cell-depleted or unmanipulated grafts: evaluation of overall and antigen-specific T-cell repertoires. Blood. 1999; 94(12):4358-4369.
14. Woolfrey AE, Anasetti C, Storer B, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood. 2002;99(6): 2002-2008. (Pubitemid 34525481)
15. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97(10):2962-2971.
16. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369(9577):1947-1954. (Pubitemid 46874578)
17. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004;22(24):4872-4880. (Pubitemid 46638610)
18. Farag SS, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant. 2006;12(8): 876-884. (Pubitemid 44070674)
19. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus- host disease without improved survival. Biol Blood Marrow Transplant. 2007;13(12):1461- 1468.
20. Schmitz N, Eapen M, Horowitz MM, et al. Longterm outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006;108(13):4288-4290. (Pubitemid 44913306)
21. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855-864. (Pubitemid 27321388)
22. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204-217. (Pubitemid 10036817)
23. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. (Pubitemid 41754712)
24. Weisdorf D, Spellman S, Haagenson M, et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. 2008;14(7):748-758. (Pubitemid 351773151)
25. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
26. Cox DR. The Analysis of Binary Data. London, United Kingdom: Methuen; 1970.
27. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graftversus- host disease according to National Institutes of Health consensus criteria. Blood. 2011; 117(11):3214-3219.
28. Anasetti C, Rybka W, Sullivan KM, Banaji M, Slichter SJ. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood. 1989;73(4):1054-1058. (Pubitemid 19078388)
29. Browning B, Thormann K, Tse W, Duerst R, Kletzel M, Jacobsohn D. Weight loss in pediatric patients with chronic graft-versus-host disease (cGVHD). Biol Blood Marrow Transplant. 2005; 11(2 suppl 1):71.
30. Jacobsohn DA, Margolis J, Doherty J, Anders V, Vogelsang GB. Weight loss and malnutrition in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2002;29(3):231-236. (Pubitemid 34189515)
31. Zauner C, Rabitsch W, Schneeweiss B, et al. Energy and substrate metabolism in patients with chronic extensive graft-versus-host disease. Transplantation. 2001;71(4):524-528. (Pubitemid 32207203)
32. Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 2011;62:265-279.
33. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: longterm follow-up of a randomized trial. Blood. 2002; 100(2):415-419. (Pubitemid 34761101)
34. Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus- host disease. Blood. 1997;90(12):4705-4709.
35. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graftversus- host disease. Blood. 2004;104(12):3501-3506. (Pubitemid 39564419)
36. Thepot S, Zhou J, Perrot A, et al. The graftversus- leukemia effect is mainly restricted to NIHdefined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010;24(11): 1852-1858.